Evidence map›Paper›PMID 33571843›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2021

A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants.

José A González-Feliciano, Coral M Capó-Vélez, Pearl Akamine, Manuel Delgado-Vélez, Ruth Almodóvar, Javier Rivera, Ignacio Pino, Gloriner Morell, Daniel Eichinger, José H Rivera and 2 more

Abstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

José A González-FelicianoMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Coral M Capó-VélezMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Pearl AkamineMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Manuel Delgado-VélezMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Ruth AlmodóvarCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Javier RiveraCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Ignacio PinoCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Gloriner MorellCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Daniel EichingerCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
José H RiveraCDI Laboratories, 12 W Méndez Vigo Ave. Mayagüez, PR 00680, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
José A Lasalde-DominicciMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Department of Biology, University of Puerto Rico, Río Piedras Campus, San Juan, PR 00926, USA; Department of Chemistry, University of Puerto Rico, Río Piedras Campus, San Juan, PR 00925, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA.
Abel Baerga-OrtizMolecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; Department of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936-5067, USA; Clinical Bioreagent Center, University of Puerto Rico, San Juan, PR, 00926, USA. Electronic address: abel.baerga@upr.edu.

Funding

SUPPLEMENT FOR RENOVATION OF ANIMAL FACILITIES AT INSTITUTE OF NEUROBIOLOGYG12RR003051 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CONDE, JOSE G · 1986 to 2011
$28.1M
The Role of Sensory Input to Mammalian Locomotion After the Loss of supraspinal.P20GM103642 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI LASALDE-DOMINICCI, JOSE ANTONIO · 2013 to 2023
$20.6M
Optimization of HIV glycoproteins as vaccine candidatesR01AI122935 · NIAID · UNIVERSITY OF PUERTO RICO · PI BAERGA-ORTIZ, ABEL J, LASALDE-DOMINICCI, JOSE ANTONIO · 2016 to 2019
$5.5M
NCRR NIH HHS G12 RR003051NIAID NIH HHS R01 AI122935NIGMS NIH HHS P20 GM103642
6 · The paper itself

Abstract

A reversed phase high performance liquid chromatography (RP-HPLC) method was developed for the quantitative determination of recombinant HIV-1 gp145 produced in CHO-K1 cells, as measured directly from culture supernatants. Samples were diluted in 50% D-PBS and 50% PowerCHO-2 (PC2) spent medium, and resolved on a Zorbax 300SB-C8 Rapid Resolution (2.1 × 50 mm, 3.5 µm) column, fitted with a C8 guard column (Zorbax 300SB-C8, 2.1 × 12.5 mm, 5 µm), using 0.1% TFA and 2% n-propanol in LC-MS water as mobile phase A and 0.1% TFA, 70% isopropanol, and 20% acetonitrile in LC-MS water as mobile phase B. The column temperature was 80 °C, the flow rate was 0.4 mL/min and the absorbance was monitored at 280 nm. The procedures and capabilities of the method were evaluated against the criteria for linearity, limit of detection (LOD), accuracy, repeatability, and robustness as defined by the International Conference on Harmonization (ICH) 2005 Q2(R1) guidelines. Two different variants of the HIV-1 envelope protein (Env), CO6980v0c22 gp145 and SF162 gp140, were analyzed and their retention times were found to be different. The method showed good linearity (R

Indexed as

AnimalsCell Culture TechniquesCHO CellsChromatography, High Pressure LiquidChromatography, Reverse-PhaseCricetinaeCricetulusenv Gene Products, Human Immunodeficiency VirusLimit of DetectionLinear ModelsRecombinant ProteinsReproducibility of Resultsenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1Recombinant ProteinsEnvGlycoproteingp145HIV vaccineVaccine production titer

Identifiers

PMID33571843
PMCPMC8041096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.